Literature DB >> 7745466

Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

M Yamamoto1, R Sawaya, S Mohanam, V H Rao, J M Bruner, G L Nicolson, K Ohshima, J S Rao.   

Abstract

The plasminogen activation system consists of plasminogen activators and their inhibitors, serine proteases, and serpins. The proteases and inhibitors regulate a variety of processes in tissue morphogenesis, differentiation, cell migration, and cancer cell invasiveness and metastasis. One of the plasminogen activators, urokinase-type plasminogen activator (uPA), binds to a specific surface and provides a localized cell surface proteolytic activity required for the destruction of extracellular matrix, which is a vital step in tumor cell invasion. The proteolytic activity of uPA is modulated by its cell surface receptor, as well as by plasminogen activator inhibitor type-1 (PAI-1) and, to a lesser degree, by other inhibitors. The role of plasminogen activators and their inhibitors in cancer invasion can be demonstrated in the development and progression of malignant brain tumors. Our findings indicate that uPA and PAI-1 expression are dramatically upregulated in malignant brain tumors in parallel with the histological progression of the tumors. The results suggest that these molecules may contribute to tumor invasion in addition to their significant role in angiogenesis. An evaluation of the plasminogen activation system could add diagnostic and prognostic significance to the evaluation of individual patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7745466     DOI: 10.1007/BF01052889

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  151 in total

1.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation.

Authors:  J Herz; D E Clouthier; R E Hammer
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

Review 2.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

3.  Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids.

Authors:  N Busso; D Belin; C Failly-Crépin; J D Vassalli
Journal:  J Biol Chem       Date:  1986-07-15       Impact factor: 5.157

4.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.

Authors:  C F Sier; H W Verspaget; G Griffioen; J H Verheijen; P H Quax; G Dooijewaard; P A De Bruin; C B Lamers
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

5.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

6.  Prevention of metastasis by inhibition of the urokinase receptor.

Authors:  C W Crowley; R L Cohen; B K Lucas; G Liu; M A Shuman; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.

Authors:  K Shirasuna; M Saka; Y Hayashido; H Yoshioka; T Sugiura; T Matsuya
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue.

Authors:  M Keeton; Y Eguchi; M Sawdey; C Ahn; D J Loskutoff
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

9.  The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.

Authors:  P Burtin; G Chavanel; J André-Bougaran; A Gentile
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

10.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  5 in total

1.  Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.

Authors:  Y Go; S K Chintala; A Rayford; E Gagercas; F Ali-Osman; B Venkaiah; R Sawaya; Z Gokaslan; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  An antigenic recombinant serine protease from Trichinella spiralis induces protective immunity in BALB/c mice.

Authors:  Xin Li; Jian-ping Yao; Ai-hua Pan; Wei Liu; Xu-chu Hu; Zhong-dao Wu; Xing-wang Zhou
Journal:  Parasitol Res       Date:  2013-07-05       Impact factor: 2.289

3.  Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.

Authors:  Sreelatha Gopinath; Rama Rao Malla; Christopher S Gondi; Kiranmai Alapati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

4.  Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

Review 5.  Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Authors:  Adel Gouri; Aoulia Dekaken; Khalid El Bairi; Arifa Aissaoui; Nihad Laabed; Mohamed Chefrour; Joseph Ciccolini; Gérard Milano; Sadek Benharkat
Journal:  Biomark Insights       Date:  2016-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.